Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey T Gibney

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Expert Opinion on Pharmacotherapy|January 25, 2014
Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?Sarah Sloot, Inna V Fedorenko, Keiran S M Smalley, et al.
Melanoma Research|June 21, 2014
Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanomaInna V Fedorenko, Bin Fang, John M Koomen, et al.
Nature Reviews. Clinical Oncology|May 29, 2013
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanomaGeoffrey T Gibney, Jane L Messina, Inna V Fedorenko, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 28, 2019
Linear IgA Disease of the Gingiva Following Nivolumab TherapySushma Jonna, Mirdza Neiders, Suresh Lakshmanan, et al.
Proteomics|October 24, 2014
Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanomaInna V Fedorenko, Bin Fang, Ana Cecelia Munko, et al.
Pigment Cell & Melanoma Research|August 19, 2014
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanomaVito W Rebecca, Gretchen M Alicea, Kim H T Paraiso, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 1, 2013
Novel treatments for melanoma brain metastasesRajappa S Kenchappa, Nam Tran, Nikhil G Rao, et al.
The Oncologist|November 23, 2020
A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain MetastasisJ Randall Patrinely, Elisa Funck-Brentano, Khang Nguyen, et al.
Cancer Medicine|May 21, 2015
Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world settingGeoffrey T Gibney, Geneviève Gauthier, Charles Ayas, et al.
Frontiers in Oncology|January 31, 2022
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint TherapyAidan M Burke, Michael Carrasquilla, Walter C Jean, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Expert Opinion on Pharmacotherapy|January 25, 2014
Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?Sarah Sloot, Inna V Fedorenko, Keiran S M Smalley, et al.
Melanoma Research|June 21, 2014
Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanomaInna V Fedorenko, Bin Fang, John M Koomen, et al.
Nature Reviews. Clinical Oncology|May 29, 2013
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanomaGeoffrey T Gibney, Jane L Messina, Inna V Fedorenko, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 28, 2019
Linear IgA Disease of the Gingiva Following Nivolumab TherapySushma Jonna, Mirdza Neiders, Suresh Lakshmanan, et al.
Proteomics|October 24, 2014
Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanomaInna V Fedorenko, Bin Fang, Ana Cecelia Munko, et al.
Pigment Cell & Melanoma Research|August 19, 2014
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanomaVito W Rebecca, Gretchen M Alicea, Kim H T Paraiso, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 1, 2013
Novel treatments for melanoma brain metastasesRajappa S Kenchappa, Nam Tran, Nikhil G Rao, et al.
The Oncologist|November 23, 2020
A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain MetastasisJ Randall Patrinely, Elisa Funck-Brentano, Khang Nguyen, et al.
Cancer Medicine|May 21, 2015
Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world settingGeoffrey T Gibney, Geneviève Gauthier, Charles Ayas, et al.
Frontiers in Oncology|January 31, 2022
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint TherapyAidan M Burke, Michael Carrasquilla, Walter C Jean, et al.
Pageof 6